Free Trial
NASDAQ:ISRG

Intuitive Surgical (ISRG) Stock Price, News & Analysis

Intuitive Surgical logo
$535.67 +8.06 (+1.53%)
(As of 10:34 AM ET)

About Intuitive Surgical Stock (NASDAQ:ISRG)

Key Stats

Today's Range
$526.61
$535.77
50-Day Range
$471.23
$537.80
52-Week Range
$304.50
$544.38
Volume
312,449 shs
Average Volume
1.46 million shs
Market Capitalization
$190.79 billion
P/E Ratio
86.12
Dividend Yield
N/A
Price Target
$524.61
Consensus Rating
Moderate Buy

Company Overview

Intuitive Surgical, Inc. is a leading medical technology company specializing in robotic-assisted surgical systems. Founded in 1995, the company's mission is to improve patient outcomes through the use of innovative technology and minimally invasive surgical techniques. Headquartered in Sunnyvale, California, Intuitive Surgical operates globally, serving healthcare professionals and patients in over 60 countries.

Intuitive Surgical's flagship product is the da Vinci Surgical System, a robotic platform that enables surgeons to perform complex procedures with enhanced precision, control, and visualization. The system consists of robotic arms controlled by the surgeon, along with a high-definition 3D camera and specialized surgical instruments. This advanced technology allows for smaller incisions, reduced scarring, shorter recovery times, and improved clinical outcomes.

The company's target market primarily includes hospitals and surgical centers specializing in urology, gynecology, general, and thoracic surgery. Intuitive Surgical has established itself as a leader in these fields and has a strong customer base, including prestigious medical institutions and renowned surgeons. The company's dedication to innovation and patient care has garnered numerous accolades, including recognition as one of Fortune's "World's Most Admired Companies" in the healthcare industry.

Intuitive Surgical is led by an experienced management team committed to driving the company's growth and maintaining its position as a leader in surgical robotics. Dr. Gary Guthart is the Chief Executive Officer and has been instrumental in guiding the company's strategic direction. Under his leadership, Intuitive Surgical has expanded its product portfolio, entered new markets, and achieved remarkable financial success.

Intuitive Surgical has consistently delivered strong financial performance over the past few years. The company's revenue has experienced steady growth, reaching $6.22 billion in the latest fiscal year. With a strong focus on operational efficiency, Intuitive Surgical has maintained healthy profit margins, enabling it to invest in research and development and expand its market reach.

The company has a solid balance sheet with manageable debt levels. This provides stability and financial flexibility for future investments and acquisitions. Intuitive Surgical's financial performance is notably impressive compared to industry benchmarks, reflecting its strong market position and competitive advantage.

Intuitive Surgical commands a premium compared to its industry peers. The company's price-to-earnings ratio, a commonly used valuation measure, is higher than average due to its strong growth prospects and dominant market position. Investors have recognized the company's innovation and potential for long-term success, contributing to its higher valuation.

Intuitive Surgical has exhibited remarkable stock performance in recent years. The company's share price has experienced significant growth, reflecting investor confidence in its business model and growth potential. Notably, the stock has outperformed broader market indices and many of its industry peers.

Intuitive Surgical operates in the rapidly evolving field of surgical robotics, which is transforming the healthcare landscape. The industry is characterized by intense competition, with major players including Medtronic, Johnson & Johnson, and Stryker Corporation. These companies continually invest in research and development to enhance their robotic surgical systems and expand their market presence.

Regulatory and political factors also play a significant role in the industry. Government agencies, such as the U.S. Food and Drug Administration (FDA), regulate the approval and safety of robotic surgical systems. Changes in regulations or introducing new policies can impact the industry landscape and market access for companies like Intuitive Surgical.

Despite the competitive landscape, Intuitive Surgical maintains a solid competitive advantage. The company's pioneering da Vinci Surgical System has established a dominant position in the market, with a large installed base worldwide. This gives Intuitive Surgical a significant edge in terms of customer loyalty and brand recognition. Additionally, the company's focus on continuous innovation and product development enables it to stay ahead of the competition.

Acquisitions and strategic partnerships offer growth opportunities for Intuitive Surgical. The company has a strong balance sheet enabling it to pursue strategic acquisitions that complement its existing product portfolio or provide access to new markets. Collaborating with other medical technology companies or research institutions can also fuel innovation and open doors to novel surgical solutions.

Like any company operating in the healthcare industry, Intuitive Surgical faces various risks and challenges. One significant risk is the potential for changes in healthcare policies and reimbursement rates. Government policies can directly impact the adoption and utilization of robotic surgical systems, which could affect the demand for Intuitive Surgical's products.

Another challenge is emerging new technologies or surgical techniques that may compete with or disrupt the robotic-assisted surgery market. Technological advancements in artificial intelligence and virtual reality could offer alternative solutions to traditional surgical procedures. Intuitive Surgical must stay at the forefront of innovation and adapt its offerings to remain competitive.

Additionally, the company faces the risk of product recalls or safety concerns. As robotic surgical systems become more complex, ensuring their reliability and patient safety becomes paramount. Intuitive Surgical must continue to invest in quality control measures, regulatory compliance, and ongoing training for surgeons to mitigate these risks.

Intuitive Surgical Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
94th Percentile Overall Score

ISRG MarketRank™: 

Intuitive Surgical scored higher than 94% of companies evaluated by MarketBeat, and ranked 106th out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Intuitive Surgical has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 13 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Intuitive Surgical has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Intuitive Surgical's stock forecast and price target.
  • Earnings Growth

    Earnings for Intuitive Surgical are expected to grow by 15.60% in the coming year, from $5.45 to $6.30 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Intuitive Surgical is 84.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Intuitive Surgical is 84.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.51.

  • Price to Earnings Growth Ratio

    Intuitive Surgical has a PEG Ratio of 5.19. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Intuitive Surgical has a P/B Ratio of 11.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Intuitive Surgical's valuation and earnings.
  • Percentage of Shares Shorted

    1.08% of the outstanding shares of Intuitive Surgical have been sold short.
  • Short Interest Ratio / Days to Cover

    Intuitive Surgical has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Intuitive Surgical has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Intuitive Surgical does not currently pay a dividend.

  • Dividend Growth

    Intuitive Surgical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.08% of the outstanding shares of Intuitive Surgical have been sold short.
  • Short Interest Ratio / Days to Cover

    Intuitive Surgical has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Intuitive Surgical has recently increased by 8.45%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Intuitive Surgical has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 45 news articles for Intuitive Surgical this week, compared to 18 articles on an average week.
  • Search Interest

    60 people have searched for ISRG on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • MarketBeat Follows

    46 people have added Intuitive Surgical to their MarketBeat watchlist in the last 30 days. This is an increase of 142% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Intuitive Surgical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $45,897,071.00 in company stock.

  • Percentage Held by Insiders

    Only 0.90% of the stock of Intuitive Surgical is held by insiders.

  • Percentage Held by Institutions

    83.64% of the stock of Intuitive Surgical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Intuitive Surgical's insider trading history.

ISRG Stock News Headlines

5 Stocks that could triple in a week
Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here.
Abbott Laboratories logo and sign near company office in Silicon Valley. Abbott Labs is an American health care company. - Sunnyvale, California, USA , 2022 — Stock Editorial Photography
These Are The Top Health Stocks to Own for Buy-and-Hold Investing (ISRG)
The stocks on this list are the top three buy-and-hold stocks in healthcare, producing significant value for shareholders while leading their respective fields.
See More Headlines

ISRG Stock Analysis - Frequently Asked Questions

Intuitive Surgical's stock was trading at $337.36 at the beginning of 2024. Since then, ISRG shares have increased by 56.5% and is now trading at $528.00.
View the best growth stocks for 2024 here
.

Intuitive Surgical, Inc. (NASDAQ:ISRG) announced its quarterly earnings data on Thursday, October, 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.32. The medical equipment provider earned $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a trailing twelve-month return on equity of 13.41% and a net margin of 28.51%.

Intuitive Surgical shares split on the morning of Tuesday, October 5th 2021. The 3-1 split was announced on Thursday, August 5th 2021. The newly minted shares were distributed to shareholders after the closing bell on Monday, October 4th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Intuitive Surgical subsidiaries include these companies: Orpheus Medical, NeoGuide Systems, Computer Motion, Intuitive Surgical AB, Intuitive Surgical ApS, Intuitive Surgical Australia Proprietary Limited, Intuitive Surgical Brasil Importacao E Comercio De Equipamentos Cirurgicos Ltda, and others.

Top institutional investors of Intuitive Surgical include State Street Corp (4.23%), FMR LLC (3.08%), Geode Capital Management LLC (2.11%) and Fisher Asset Management LLC (1.34%). Insiders that own company stock include David J Rosa, Marshall Mohr, Alan J Levy, Gary S Guthart, Mark J Rubash, Amal M Johnson, Jamie Samath, Brian Edward Miller, Robert Desantis, Henry L Charlton, Gary Loeb, Amy L Ladd, Myriam Curet, Mark Brosius, Fredrik Widman and Craig H Barratt.
View institutional ownership trends
.

Shares of ISRG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Intuitive Surgical investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), NVIDIA (NVDA), UnitedHealth Group (UNH), The Goldman Sachs Group (GS) and Meta Platforms (META).

Company Calendar

Last Earnings
10/17/2024
Today
11/18/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
1/28/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ISRG
CUSIP
46120E60
Employees
13,676
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$524.61
High Stock Price Target
$604.00
Low Stock Price Target
$375.00
Potential Upside/Downside
-0.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
18 Analysts

Profitability

Net Income
$1.80 billion
Pretax Margin
30.25%

Debt

Sales & Book Value

Annual Sales
$7.12 billion
Cash Flow
$5.42 per share
Book Value
$44.02 per share

Miscellaneous

Free Float
352,973,000
Market Cap
$187.92 billion
Optionable
Optionable
Beta
1.39

Social Links


This page (NASDAQ:ISRG) was last updated on 11/18/2024 by MarketBeat.com Staff
From Our Partners